Educational Objectives

Recall the pathophysiology and clinical manifestations of Duchenne muscular dystrophy (DMD), as well as the burden of DMD and its impact on patient quality of life
List the latest updates for the safety and efficacy data of new and approved disease-modifying therapies in the treatment of DMD

Faculty:

Amanda Hickman, PharmD, MPH, MSCS

Central Support Pharmacist – Neuro/Psych/Sleep

Trellis Rx

Atlanta, Georgia

Moderator:

Jessica L. Kerr, PharmD, CDCES

Associate Dean – Office Professional and Student Affairs

Professor/Clinical Pharmacist

Southern Illinois University Edwardsville

School of Pharmacy

Edwardsville, Illinois

Amanda Hickman, PharmD, MPH, MSCS, and Jessica L. Kerr, PharmD, CDCES, have no financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEU) under the ACPE universal activity number 0290-0000-22-613-H01-P. The activity is available for CE credit through December 22, 2023.

This activity is supported by an educational grant from Sarepta Therapeutics.

Treatment of Duchenne Muscular Dystrophy: Updates in Disease-Modifying Drugs | PTCE Pharmacy Connect